Neurotrack

by Neurotrack  · Based in United States → — Cognitive care enablement. Giving providers the confidence to act earlier.
Geriatrics Neurology Psychiatry
Website
Claim this tool
Is this the maker? Claim the company →

Overview

Neurotrack is a cognitive care enablement platform that equips providers to assess, diagnose, and care for people living with Mild Cognitive Impairment (MCI) and dementia, earlier and with greater accuracy. The platform combines clinically validated assessments, Smart Logic adaptive technology, and care planning support in a single workflow-embedded solution. Smart Logic is Neurotrack’s adaptive intelligence layer that determines which assessments to administer, surfaces a structured diagnostic pathway, and supports personalized care planning — all within a single clinical encounter. Neurotrack aims to close the confidence gap in cognitive care by providing providers with clinically validated assessments, diagnostic clarity, and care planning support to identify cognitive decline earlier.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Clinically validated digital assessments
  • Smart Logic adaptive technology
  • Care planning support
  • Earlier detection of cognitive impairment
  • Structured diagnostic pathways
  • Patient-specific care plans
  • EHR integration
  • Webcam-based eye tracking
  • Digital task batteries for processing speed, executive function, and verbal memory
  • Asynchronous remote assessment with environmental-distraction detection

Use Cases

  • Early detection of cognitive impairment and dementia
  • Diagnosis of MCI and dementia
  • Care planning for individuals with cognitive decline
  • Longitudinal monitoring of cognitive function
  • Integration into annual wellness visits
  • Supporting accurate V28 coding for health plans

What Physicians Need to Know

Evidence Base
Neurotrack's platform is built on over a decade of peer-reviewed research, clinical validation, and scientific rigor. Its capabilities are directly traceable to published science and validated methodology. The co-founders and clinical team have collectively authored 354 peer-reviewed papers, cited over 37,000 times. Neurotrack has also been awarded $4.3 million in grants from the National Institute on Aging, ADDF, and Georgia Research Alliance.
Clinical Validation Studies
Neurotrack's cognitive assessment battery demonstrates 94% sensitivity and 90% specificity, exceeding Alzheimer's Association guidelines for Brief Cognitive Assessments. Studies published in 'Frontiers in Aging Neuroscience' (2023) and 'JMIR Aging' (2023) validate its digital screening against gold standard measures and confirm its reliability for repeat use. The assessments are validated across diverse populations, including underrepresented groups, and for asynchronous remote administration.
Alert Fatigue Management
Neurotrack's 'Smart Logicu2122' adaptive intelligence layer dynamically determines which assessments to administer based on patient responses, tailoring the evaluation in real time. This adaptive approach reduces unnecessary assessment steps, saving time and creating a more comfortable experience for patients, which can indirectly help manage alert fatigue by streamlining the assessment process.
Override Rate Data
Neurotrack's 'Smart Logicu2122' supports clinical decision-making by synthesizing assessment findings with EHR context (comorbidities, medications, mental health status) to surface a structured clinical pathway aligned with DSM-5 and CMS guidelines. It provides interpretive support and diagnostic confidence, but 'never directs' clinical decision-making, implying that clinicians retain the ability to override suggestions.
Drug Interaction Checking
Neurotrack's 'Smart Logicu2122' synthesizes assessment findings with full EHR context, which includes medications. While it doesn't explicitly state 'drug interaction checking' as a feature, the inclusion of medication review in its diagnostic support suggests it considers medication context.
Differential Diagnosis Support
Neurotrack's 'Smart Logicu2122' synthesizes assessment findings with full EHR context, including comorbidities, medications, and mental health status, to surface a structured clinical pathway aligned with DSM-5 and CMS guidelines. This provides interpretive support and diagnostic confidence to help providers in differential diagnosis.
Guideline Update Frequency
Neurotrack's decision support features are aligned with guidelines from the DSM-5, CMS, Alzheimer's Association, and American Academy of Neurology. The company emphasizes its commitment to closing the cognitive care confidence gap through clinically validated assessments and education, suggesting an ongoing alignment with current guidelines and best practices.
Clinical Workflow Integration
Neurotrack integrates directly into existing EHR environments, embedding cognitive assessments and care planning support into clinical workflows. It generates structured clinical documentation that automatically flows into the patient record, including assessment results, DSM-5 aligned documentation, and care planning outputs. Assessments can be administered in-clinic, remotely, or at home.
Decision Audit Trail
Neurotrack generates objective scores, clinical interpretations, and RADV-ready records that satisfy V28 requirements, supporting compliant billing and audit-ready documentation. The platform collects data and video of each test administration, allowing clinicians to review the administration and results along with contextual information.
Physician Tip

Neurotrack's clinically validated digital assessments offer high sensitivity (94%) and specificity (90%) for detecting cognitive impairment at the MCI stage, outperforming traditional paper-based tools. Leverage its EHR integration to streamline cognitive screening and care planning within your existing workflow, reducing administrative burden and saving time. The 'Smart Logicu2122' feature provides adaptive assessment and structured clinical pathways, enhancing diagnostic confidence and supporting personalized care plans. Utilize the platform for annual wellness visits, as it's designed for routine use and reimbursable under Medicare. The ability to administer assessments remotely or in-home can improve patient access and engagement.

Neurotrack directly integrates with major EHR platforms, ensuring that assessment results, DSM-5 aligned documentation, and care planning outputs are automatically incorporated into the patient record. This seamless integration is designed to work within existing infrastructure, making adoption straightforward for clinical and operations teams.

Details

Category Clinical Decision Support & Reference, Neurology AI
Pricing Unknown — unknown
DeploymentCloud-based
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status Unknown AI-estimated

Neurotrack is registered as an FDA Class II medical device, meeting regulatory standards for clinical diagnostic tools. This registration was received in 2020.
Integrations
EHR Not specified
Specialties Geriatrics, Neurology, Psychiatry

What the Web Says

Neurotrack offers a digital cognitive assessment and personalized programs to detect early signs of cognitive decline and support brain health, particularly for adults aged 50 and older concerned about cognitive health or with a family history of Alzheimer's disease. The platform utilizes eye-tracking technology to measure subtle changes in visual behavior associated with memory function, specifically in the hippocampus. Neurotrack aims to provide accessible, non-invasive screening and actionable steps for individuals to improve their brain health.

Overall: Mixed

Strengths

  • Non-invasive and accessible assessment method using eye-tracking technology.
  • Provides personalized programs with actionable steps for brain health, including cognitive training, nutritional guidance, and lifestyle recommendations.
  • Potential for early detection of cognitive impairment, differentiating it from standard methods.
  • Can be administered remotely or in-clinic, offering flexibility and frequent monitoring.
  • Clinically validated assessments backed by scientific research.
  • Integration with clinical workflows and EHR systems is possible.

Limitations

  • Reliance on eye-tracking as a sole indicator of cognitive function can be limiting.
  • The cognitive score is a relative measure and does not definitively diagnose any condition; further medical evaluation is needed for a comprehensive diagnosis.
  • Effectiveness of personalized programs is still under ongoing research, and individual impact can vary.
  • VR headset requirement for some assessments may be a barrier for some users, especially older adults.
  • Accuracy of the imprint assessment requires further validation through large-scale longitudinal studies.
  • Some reviews mention uncertainty in business and finance, and lack of transparency with employees.

Based on reviews from: Neurotrack.com, YouTube, Scam Detector, Indeed.com, Emory University, MATTER Chicago, PitchBook, PR Newswire, Digital Health, Reddit, PubMed, Capterra, G2, TooliQ.ai

Last updated: 2026-09-10

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Neurotrack

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Neurotrack Blog
Blood Biomarkers Are Finally Here. They Still Can't Tell Us Who Is Cognitively Impaired.
This blog post discusses the arrival of blood biomarkers for cognitive health but highlights their limitations in identifying individuals with cognitive impairment.
2026-09
NeuroTrax
Bringing Brain Science into the Clinic with NeuroTrax and TMS-EEG
This article discusses combining NeuroTrax digital cognitive neurometrics with TMS-EEG to gain a more complete understanding of brain health and cognitive risk in older adults.
2026-08
Neurotrack White Paper
The Hidden Cost of Undetected Cognitive Decline
A Neurotrack white paper quantifies the financial impact of undiagnosed cognitive decline, particularly for Medicare Advantage plans.
2026-08
Neurotrack White Paper
Closing the Cognitive Care Gap
This white paper from Neurotrack addresses the gap in cognitive care, likely discussing solutions and strategies to improve detection and management of cognitive decline.
2026-08
Neurotrack Blog
The Critical Case for Cognitive Screening: Why Early Detection Changes Everything
This article emphasizes the importance of routine cognitive screening for transforming patient outcomes and reducing healthcare costs by enabling early intervention for cognitive decline.
2025-08
Neurotrack
Elli Kaplan to Speak on Innovations in Dementia Detection
Neurotrack announced that its Co-founder and CEO, Elli Kaplan, will be speaking on innovations in dementia detection.
2024-10
Neurotrack
Three-minute online cognitive screening simplifies long-term care underwriting
Neurotrack announced a three-minute online cognitive screening tool designed to simplify long-term care underwriting.
2023-12
Neurotrack
Neurotrack Expands C-suite with New Chief Growth Officer
Neurotrack announced the expansion of its C-suite with the appointment of a new Chief Growth Officer.
2023-05

Videos

Product demos, reviews, and walkthroughs for Neurotrack.

View all on YouTube

Frequently Asked Questions

Neurotrack leverages AI to analyze digital biomarkers from patient interactions, such as eye-tracking and cognitive task performance, to detect subtle changes indicative of cognitive decline. The AI models are trained on large datasets to identify patterns, and the company employs proprietary algorithms designed to enhance diagnostic accuracy and mitigate potential biases in the assessment process.
Neurotrack is committed to regulatory compliance, including HIPAA for patient data privacy and security. The company has obtained CE Mark as a Class I Medical Device in Europe, and is pursuing FDA clearance in the United States for its AI-driven diagnostic tools. Data security is maintained through encryption, access controls, and regular security audits.
Clinical alternatives to Neurotrack include traditional pen-and-paper cognitive tests like the MMSE or MoCA, as well as other digital cognitive assessment tools. Neurotrack aims to demonstrate superior efficacy through earlier and more sensitive detection of cognitive decline, potentially leading to earlier interventions. The cost-effectiveness is often highlighted by its scalability and reduced need for specialized personnel compared to extensive neuropsychological evaluations.
Neurotrack's pricing structure for healthcare providers typically involves subscription models, which may vary based on factors such as patient volume, the scope of services utilized, and integration requirements with existing electronic health record (EHR) systems. Specific pricing details are usually discussed directly with interested healthcare organizations to tailor a plan to their needs.
While Neurotrack's AI is designed for broad applicability, limitations can include its current validation across extremely diverse linguistic and cultural backgrounds, or in patients with certain severe pre-existing neurological conditions that might confound results. The company continuously works to expand its validation studies to ensure robust performance across a wider range of patient populations and clinical scenarios.
Neurotrack is designed to integrate with existing EHR systems to streamline clinical workflows. Physicians can typically order assessments directly through their EHR, and the results are then securely transmitted back into the patient's record. The workflow involves reviewing the AI-generated reports, which provide insights into cognitive function, to inform clinical decision-making and patient management plans.
Neurotrack provides comprehensive training and ongoing support to physicians and their staff. This typically includes onboarding sessions, educational materials, and access to a support team to assist with platform usage, technical issues, and interpretation of AI-generated insights. The goal is to ensure healthcare providers can effectively integrate the platform into their practice and confidently utilize its features.

Related Tools

OCTA
OCTA
Clinical Decision Support & Reference
OCTA Flow is an AI-powered platform that assists ophthalmologists in analyzing Optical Coherence Tomography Angiography (OCTA) scans to enhance diagnostic accuracy and efficiency.
Starts from $0/month (free plan) to $2,999/month (lead plan) for octa core.
Elsevier
Elsevier
Clinical Decision Support & Reference
ClinicalKey AI is a clinical decision support tool that uses artificial intelligence to provide physicians with rapid access to evidence-based medical information.
Paid subscription, with individual and institutional plans.
EvidenceMD
EvidenceMD
Clinical Decision Support & Reference
EvidenceMD is an AI-powered clinical decision support platform that provides physicians with rapid access to current and relevant medical evidence for informed decision-making.
Free, individual, max, enterprise
FAITH project
AI Agent
Clinical Decision Support & Reference
The FAITH project focuses on Federated Artificial Intelligence for Trusted Healthcare, aiming to develop secure and privacy-preserving AI solutions for healthcare, including potential applications for physician directories.
AI-based support system for skin cancer diagnostics
German Cancer Research Center (DKFZ)
Clinical Decision Support & Reference
Scientists at the German Cancer Research Center have developed an AI-based support system for skin cancer diagnostics that explains its decisions, increasing doctors' confidence in both the AI and their own diagnoses.
Prof. Valmed
Prof. Valmed - validated medical information GmbH
Clinical Decision Support & Reference
Prof. Valmed is Europe's first CE Class IIb certified AI-supported medical co-pilot, providing healthcare professionals with validated, evidence-based medical information through an innovative AI platform.
Paid subscription

See all Clinical Decision Support & Reference tools →

Suggest an Edit → | Last Verified: 2026-09-09 | First Added: 2026-09-09
AI Tool Finder
AI-powered search. Results may not be comprehensive.